Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Change in Receivables (2022 - 2025)

Arcutis Biotherapeutics has reported Change in Receivables over the past 4 years, most recently at $31.1 million for Q4 2025.

  • Quarterly results put Change in Receivables at $31.1 million for Q4 2025, up 120.25% from a year ago — trailing twelve months through Dec 2025 was $73.2 million (up 54.81% YoY), and the annual figure for FY2025 was $73.2 million, up 54.81%.
  • Change in Receivables for Q4 2025 was $31.1 million at Arcutis Biotherapeutics, up from $8.4 million in the prior quarter.
  • Over the last five years, Change in Receivables for ARQT hit a ceiling of $31.1 million in Q4 2025 and a floor of $2.2 million in Q3 2023.
  • Median Change in Receivables over the past 4 years was $7.4 million (2023), compared with a mean of $10.4 million.
  • Biggest five-year swings in Change in Receivables: surged 651.54% in 2024 and later plummeted 49.25% in 2025.
  • Arcutis Biotherapeutics' Change in Receivables stood at $6.0 million in 2022, then rose by 6.02% to $6.4 million in 2023, then skyrocketed by 121.06% to $14.1 million in 2024, then skyrocketed by 120.25% to $31.1 million in 2025.
  • The last three reported values for Change in Receivables were $31.1 million (Q4 2025), $8.4 million (Q3 2025), and $21.3 million (Q2 2025) per Business Quant data.